Cargando…
Pharmacotherapy for uveitis: current management and emerging therapy
Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181632/ https://www.ncbi.nlm.nih.gov/pubmed/25284976 http://dx.doi.org/10.2147/OPTH.S47778 |
_version_ | 1782337395726745600 |
---|---|
author | Barry, Robert J Nguyen, Quan Dong Lee, Richard W Murray, Philip I Denniston, Alastair K |
author_facet | Barry, Robert J Nguyen, Quan Dong Lee, Richard W Murray, Philip I Denniston, Alastair K |
author_sort | Barry, Robert J |
collection | PubMed |
description | Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. |
format | Online Article Text |
id | pubmed-4181632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41816322014-10-03 Pharmacotherapy for uveitis: current management and emerging therapy Barry, Robert J Nguyen, Quan Dong Lee, Richard W Murray, Philip I Denniston, Alastair K Clin Ophthalmol Review Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects. Dove Medical Press 2014-09-22 /pmc/articles/PMC4181632/ /pubmed/25284976 http://dx.doi.org/10.2147/OPTH.S47778 Text en © 2014 Barry et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Barry, Robert J Nguyen, Quan Dong Lee, Richard W Murray, Philip I Denniston, Alastair K Pharmacotherapy for uveitis: current management and emerging therapy |
title | Pharmacotherapy for uveitis: current management and emerging therapy |
title_full | Pharmacotherapy for uveitis: current management and emerging therapy |
title_fullStr | Pharmacotherapy for uveitis: current management and emerging therapy |
title_full_unstemmed | Pharmacotherapy for uveitis: current management and emerging therapy |
title_short | Pharmacotherapy for uveitis: current management and emerging therapy |
title_sort | pharmacotherapy for uveitis: current management and emerging therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181632/ https://www.ncbi.nlm.nih.gov/pubmed/25284976 http://dx.doi.org/10.2147/OPTH.S47778 |
work_keys_str_mv | AT barryrobertj pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT nguyenquandong pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT leerichardw pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT murrayphilipi pharmacotherapyforuveitiscurrentmanagementandemergingtherapy AT dennistonalastairk pharmacotherapyforuveitiscurrentmanagementandemergingtherapy |